|
gptkbp:instance_of
|
gptkb:court_cases
gptkb:legal_case
|
|
gptkbp:addresses
|
genetic discrimination
|
|
gptkbp:appeals_to
|
gptkb:U._S._Court_of_Appeals_for_the_Federal_Circuit
|
|
gptkbp:argued_on
|
gptkb:American_Civil_Liberties_Union
|
|
gptkbp:court
|
gptkb:Supreme_Court_of_the_United_States
|
|
gptkbp:decided_by
|
gptkb:United_States_Supreme_Court
June 13, 2013
|
|
gptkbp:effective_date
|
June 13, 2013
|
|
gptkbp:examines
|
patent eligibility
|
|
gptkbp:examines_issues_of
|
intellectual property rights
|
|
gptkbp:has_implications_for
|
gptkb:Health_Insurance
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Association for Molecular Pathology v. Myriad Genetics, Inc.
|
|
gptkbp:influenced_by
|
gptkb:public_opinion
|
|
gptkbp:involves
|
legal arguments
biomedical ethics
biotechnology patents
|
|
gptkbp:is_a
|
gptkb:cultural_landmark
|
|
gptkbp:is_analyzed_in
|
law reviews
|
|
gptkbp:is_applied_in
|
gptkb:U._S._District_Court_for_the_Southern_District_of_New_York
|
|
gptkbp:is_cited_in
|
subsequent cases
subsequent legal cases
|
|
gptkbp:is_discussed_in
|
gptkb:legal_case
|
|
gptkbp:is_influenced_by
|
gptkb:scientific_community
|
|
gptkbp:is_part_of
|
U. S. legal history
|
|
gptkbp:is_related_to
|
biomedical research
|
|
gptkbp:is_relevant_to
|
biotechnology ethics
|
|
gptkbp:is_significant_for
|
genetic research community
|
|
gptkbp:legal_issue
|
gene patenting
patent eligibility of human genes
|
|
gptkbp:outcome
|
invalidated gene patents
Supreme Court ruled that naturally occurring DNA cannot be patented
|
|
gptkbp:precedent
|
Myriad decision
|
|
gptkbp:related_to
|
intellectual property law
|
|
gptkbp:significance
|
impact on patent law
|
|
gptkbp:bfsParent
|
gptkb:United_States_Court_of_Appeals_for_the_Federal_Circuit
|
|
gptkbp:bfsLayer
|
5
|